Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
Codeine vs ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Codeine is an opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. It is a prodrug converted to morphine via CYP2D6, which mediates most of its analgesic effects.
Pentazocine is a mixed agonist-antagonist opioid analgesic that binds to mu, kappa, and sigma opioid receptors, primarily acting as an agonist at kappa receptors and partial agonist at mu receptors, resulting in analgesic and sedative effects. Acetaminophen (paracetamol) is an analgesic and antipyretic whose mechanism involves inhibition of cyclooxygenase (COX) enzymes, primarily COX-2, in the central nervous system, and possibly activation of descending serotonergic pathways.
FDA-approved for mild to moderate pain where an opioid is appropriate,FDA-approved for cough suppression,Off-label: acute pain, chronic pain (limited use)
Moderate to severe pain where an opioid analgesic is appropriate
Oral: 30-60 mg every 4-6 hours as needed; maximum 360 mg per day. Intramuscular/Subcutaneous: 30-60 mg every 4-6 hours as needed. Use lowest effective dose for shortest duration.
One tablet (acetaminophen 500 mg / pentazocine hydrochloride 25 mg) orally every 4 hours as needed for pain; maximum daily dose: acetaminophen 4000 mg (8 tablets) and pentazocine hydrochloride 200 mg (8 tablets).
The terminal elimination half-life of codeine is approximately 2.5 to 3.5 hours in adults with normal renal function. In patients with renal impairment, the half-life may be prolonged to up to 8 hours, necessitating dose adjustment.
Acetaminophen: 2-3 hours (prolonged in hepatic impairment). Pentazocine: 2-3 hours (terminal), with clinical analgesic effect lasting 3-4 hours.
Codeine is metabolized by CYP2D6 to morphine (active), via CYP3A4 to norcodeine (inactive), and via glucuronidation. Morphine is further conjugated via UGT2B7.
Pentazocine is extensively metabolized in the liver via oxidation and glucuronidation; significant first-pass metabolism. Acetaminophen is metabolized primarily in the liver via conjugation with glucuronide and sulfate, and oxidation via CYP2E1, CYP1A2, and CYP3A4 to a toxic metabolite (NAPQI).
Codeine is eliminated primarily via renal excretion (about 90% as inactive metabolites, mainly codeine-6-glucuronide and norcodeine, with less than 10% as free codeine). Biliary/fecal excretion accounts for approximately 10% of the dose.
Acetaminophen: renal (2-4% unchanged, ~85% as glucuronide and sulfate conjugates). Pentazocine: renal (~60% as unchanged and conjugates), biliary/fecal (~20%).
Approximately 25% bound to plasma proteins, primarily albumin.
Acetaminophen: 10-25% (albumin). Pentazocine: 60-70% (albumin and alpha-1 acid glycoprotein).
Approximately 3-6 L/kg, indicating extensive distribution into tissues, including brain and breast milk.
Acetaminophen: 0.9 L/kg. Pentazocine: 5-7 L/kg (extensive tissue distribution).
Oral bioavailability is about 60-90% (first-pass metabolism reduces systemic exposure; extensive metabolizers may have higher morphine levels). Rectal bioavailability is similar to oral. Intramuscular and subcutaneous routes have nearly 100% bioavailability.
Acetaminophen oral: 60-90%. Pentazocine oral: ~20% (extensive first-pass metabolism). Intramuscular: pentazocine 100%.
Cr Cl 10-50 m L/min: Administer 75% of normal dose. Cr Cl <10 m L/min: Administer 50% of normal dose. Not recommended in severe renal impairment due to risk of CNS toxicity.
Cr Cl 30-50 m L/min: use with caution; decrease dose interval to every 6 hours if needed. Cr Cl <30 m L/min: restrict pentazocine; consider alternative. Not recommended for patients on dialysis.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50% or use alternative. Child-Pugh Class C: Contraindicated. Avoid in severe hepatic impairment due to decreased metabolism and risk of accumulation.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce pentazocine dose by 50%; avoid acetaminophen >2 g/day. Child-Pugh Class C: contraindicated due to acetaminophen hepatotoxicity and pentazocine accumulation.
Oral, IM, or SC: 0.5-1 mg/kg/dose every 4-6 hours as needed; maximum 60 mg/dose. Weight-based dosing for children >1 year. Not recommended in children under 12 years for postoperative tonsillectomy/adenoidectomy. Contraindicated in children <12 years for pain, and <18 for cough due to risk of respiratory depression.
Not recommended in children <12 years due to lack of safety data. For adolescents ≥12 years, adult dosing may be considered based on weight (≥50 kg).
Start at low end of dosing range (e.g., 30 mg every 4-6 hours) due to increased sensitivity and risk of respiratory depression, falls, and cognitive impairment. Monitor renal function and avoid in patients with Cr Cl <30 m L/min. Consider non-opioid alternatives first.
Reduce pentazocine dose by 50% (e.g., one tablet every 6 hours) due to increased risk of CNS depression, confusion, and constipation. Monitor renal function; avoid exceeding 4 g/day acetaminophen.
WARNING: CODEFINE HAS RISKS OF ADDICTION, ABUSE, AND MISUSE, WHICH CAN LEAD TO OVERDOSE AND DEATH. LIFE-THREATENING RESPIRATORY DEPRESSION MAY OCCUR, ESPECIALLY IN CHILDREN, AND RISK IS INCREASED WITH CYP2D6 ULTRA-RAPID METABOLIZERS. PROLONGED USE DURING PREGNANCY CAN RESULT IN NEONATAL OPIOID WITHDRAWAL SYNDROME.
Pentazocine: Risk of respiratory depression, particularly in elderly, cachectic, or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, and death. Patients should be monitored for respiratory depression and sedation.
CYP2D6 ultra-rapid metabolizers: risk of morphine toxicity, fatal respiratory depression,Life-threatening respiratory depression in children <12 years; contraindicated in <18 years for tonsillectomy/adenoidectomy,Risk of opioid-induced respiratory depression, especially in elderly, debilitated, or patients with respiratory conditions,Addiction, abuse, and misuse potential,Neonatal opioid withdrawal syndrome if used during pregnancy,Concomitant use with CNS depressants increases risk of hypotension, respiratory depression, and coma,Serotonin syndrome with serotonergic drugs,Severe hypotension, including orthostatic hypotension,Adrenal insufficiency with prolonged use,Increased risk of seizures in patients with seizure disorders,May impair ability to drive or operate machinery
Respiratory depression risk, especially in patients with compromised respiratory function,Potential for opioid dependence, abuse, and misuse,Risk of withdrawal if discontinued abruptly after prolonged use,Pentazocine may cause opioid withdrawal in patients dependent on pure mu agonists,Acetaminophen hepatotoxicity at high doses or with chronic use; risk increased with alcohol consumption or pre-existing liver disease,Central nervous system depression additive with other CNS depressants,Elderly or debilitated patients may have increased sensitivity to effects,May cause hypotension, especially in hypovolemic patients,Serotonin syndrome risk when used with serotonergic drugs,Pentazocine may cause hallucinations, confusion, or other psychotomimetic effects
Hypersensitivity to codeine or any component,Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment,Paralytic ileus (known or suspected),Postoperative management in children <18 years after tonsillectomy/adenoidectomy,Children <12 years,Use with MAOIs or within 14 days of stopping MAOIs
Hypersensitivity to either component,Severe respiratory depression (e.g., acute asthma, hypercapnia),Acute or severe bronchial asthma,Suspected surgical abdomen (may obscure diagnosis),Monoamine oxidase inhibitor (MAOI) use (current or within 14 days),Severe hepatic impairment or active liver disease (acetaminophen component),Known or suspected gastrointestinal obstruction (including paralytic ileus)
Avoid alcohol completely; increase risk of CNS depression and hepatotoxicity. Grapefruit juice may inhibit CYP3A4, affecting codeine metabolism; limited data but caution advised. High-fiber foods may help counteract constipation. No significant food restrictions aside from alcohol.
Avoid alcohol consumption due to increased risk of hepatotoxicity from acetaminophen. No specific food interactions; take with food if gastrointestinal upset occurs.
FDA Pregnancy Category C. First trimester: association with neural tube defects, cleft palate; second/third trimester: risk of fetal dependence, respiratory depression, withdrawal after birth. Avoid in labor due to neonatal respiratory depression.
Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity in any trimester. Pentazocine: Limited human data; animal studies show no teratogenicity at clinically relevant doses. However, use in third trimester may cause neonatal respiratory depression and withdrawal syndrome. Overall, risk is low but pentazocine should be avoided near term.
Codeine is excreted into breast milk; M/P ratio approximately 2.0. Use with caution; risk of infant opioid toxicity, especially in CYP2D6 ultra-rapid metabolizers. Not recommended for breastfeeding mothers.
Acetaminophen: Excreted in low amounts (M/P ratio ~0.2-0.9); compatible with breastfeeding. Pentazocine: Excreted in breast milk; M/P ratio unknown; may cause CNS effects in infants. Use with caution, especially in neonates or premature infants. Monitor infant for sedation and respiratory depression.
Increased clearance and volume of distribution in pregnancy may require higher doses for analgesia; however, avoid due to risks. No standard adjustment; use lowest effective dose for shortest duration if necessary.
Acetaminophen: No significant pharmacokinetic changes in pregnancy; standard dosing (max 3-4 g/day) applies. Pentazocine: Clearance may increase due to enhanced hepatic metabolism; dose adjustments not routinely recommended but monitor response. Avoid high doses near term due to risk of neonatal depression.
Codeine is a prodrug requiring CYP2D6 metabolism to morphine; poor metabolizers have reduced efficacy, while ultra-rapid metabolizers risk toxicity. Avoid in children <12 years for post-tonsillectomy/adenoidectomy due to fatal respiratory depression. Monitor for constipation; prescribe laxative with chronic use. Contraindicated with MAOIs and within 14 days of their discontinuation. Not effective for acute pain needing immediate relief due to variable conversion.
Pentazocine is a mixed agonist-antagonist opioid; avoid in opioid-dependent patients due to risk of precipitated withdrawal. Acetaminophen component limits total daily dose to 4 g (or less in hepatic impairment) to prevent hepatotoxicity. Monitor for respiratory depression, especially in elderly or those with COPD. Injection site reactions (e.g., sterile abscesses, fibrosis) common with repeated intramuscular use. May cause dysphoria, hallucinations, or CNS stimulation (unlike typical opioids). Contraindicated in acute porphyria due to porphyrinogenic potential.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not combine with alcohol, sedatives, or other CNS depressants (e.g., benzodiazepines) due to risk of severe drowsiness, respiratory depression, or coma.,Common side effects include constipation, nausea, dizziness, and drowsiness. Drink plenty of fluids and consider stool softeners for constipation.,Avoid driving or operating machinery until you know how codeine affects you, as it may impair judgment and coordination.,Inform your doctor if you have a history of asthma, breathing problems, liver or kidney disease, or if you are pregnant or breastfeeding.,Do not share this medication with others, especially children; accidental use can be fatal. Store securely out of reach of children.,If you miss a dose, take it as soon as you remember. If near the next dose, skip the missed one; do not double dose.,Do not stop abruptly after prolonged use; taper under medical supervision to avoid withdrawal symptoms (anxiety, sweating, insomnia, diarrhea).
Do not exceed 4 grams of acetaminophen per day from all sources (including OTC medications).,Avoid alcohol while taking this medication; risk of liver damage increases.,This medication may cause dizziness, drowsiness, or hallucinations; avoid driving or operating machinery until effects are known.,Report any signs of allergic reaction (rash, difficulty breathing) or liver issues (yellow skin/eyes, dark urine).,Do not suddenly stop if used long-term; withdrawal symptoms may occur.,If you have opioid dependence, this medication may precipitate withdrawal symptoms.,This medication may cause constipation; maintain fluid and fiber intake.
"Pirenzepine, a selective M1 muscarinic antagonist, reduces gastrointestinal motility and secretions, while codeine, an opioid agonist, also decreases gastrointestinal motility via mu-opioid receptors. Concurrent use leads to additive anticholinergic and opioid effects, resulting in enhanced risk of severe constipation, paralytic ileus, and central nervous system depression. Clinically, patients may experience exacerbated sedation, respiratory depression, and urinary retention."
"Ropinirole, a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome, may reduce the analgesic efficacy of codeine. This is likely due to pharmacodynamic antagonism at central dopamine and opioid receptors, as well as potential pharmacokinetic interactions that decrease the conversion of codeine to its active metabolite morphine via CYP2D6 inhibition by ropinirole. The resultant blunted opioid response can lead to inadequate pain control, necessitating dose adjustment or alternative therapy."
"Vemurafenib induces CYP3A4, significantly reducing the plasma concentrations of codeine, which is metabolized via CYP3A4 to its active metabolite morphine. This may diminish codeine's analgesic efficacy, potentially leading to inadequate pain control. Additionally, reduced formation of morphine may lower the risk of opioid-related adverse effects."
"Pentazocine, a mixed opioid agonist-antagonist, may attenuate the central nervous system (CNS) stimulant effects of dextroamphetamine by competitively blocking mu-opioid receptors and potentially altering dopamine release, leading to reduced analgesic efficacy of pentazocine and diminished therapeutic response to dextroamphetamine in treating attention deficit hyperactivity disorder (ADHD) or narcolepsy. This interaction can result in suboptimal pain control and exacerbation of ADHD symptoms, requiring dose adjustments or alternative therapies."
"The concurrent use of ipratropium, an anticholinergic agent, and pentazocine, a mixed opioid agonist-antagonist, may lead to an increased risk of central nervous system (CNS) depression and anticholinergic adverse effects. Pentazocine can enhance the sedative and respiratory depressant effects of ipratropium, while ipratropium may potentiate pentazocine's anticholinergic actions, such as dry mouth, blurred vision, constipation, and urinary retention. Clinically, this interaction can result in excessive sedation, confusion, and impaired cognitive and motor function, particularly in elderly or debilitated patients."
"The combination of pentazocine, a mixed agonist-antagonist opioid, with triazolam, a benzodiazepine, can lead to additive central nervous system (CNS) depression, including increased sedation, respiratory depression, and psychomotor impairment. This is due to the synergistic effects of both drugs on GABAergic and opioid receptors in the brainstem and cortex. Clinically, this may result in excessive drowsiness, confusion, ataxia, and an elevated risk of falls or respiratory compromise, particularly in elderly or debilitated patients."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about Codeine vs ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE, answered by our medical review team.
Codeine is a Opioid Agonist that works by Codeine is an opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. It is a prodrug converted to morphine via CYP2D6, which mediates most of its analgesic effects.. ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE is a Opioid Agonist-Antagonist that works by Pentazocine is a mixed agonist-antagonist opioid analgesic that binds to mu, kappa, and sigma opioid receptors, primarily acting as an agonist at kappa receptors and partial agonist at mu receptors, resulting in analgesic and sedative effects. Acetaminophen (paracetamol) is an analgesic and antipyretic whose mechanism involves inhibition of cyclooxygenase (COX) enzymes, primarily COX-2, in the central nervous system, and possibly activation of descending serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between Codeine and ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of Codeine is: Oral: 30-60 mg every 4-6 hours as needed; maximum 360 mg per day. Intramuscular/Subcutaneous: 30-60 mg every 4-6 hours as needed. Use lowest effective dose for shortest duration.. The standard adult dose of ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE is: One tablet (acetaminophen 500 mg / pentazocine hydrochloride 25 mg) orally every 4 hours as needed for pain; maximum daily dose: acetaminophen 4000 mg (8 tablets) and pentazocine hydrochloride 200 mg (8 tablets).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining Codeine and ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE. The risk or severity of adverse effects can be increased when Codeine is combined with Pentazocine. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. Codeine is classified as Category D/X. FDA Pregnancy Category C. First trimester: association with neural tube defects, cleft palate; second/third trimester: risk of fetal dependence, respiratory depression, withdrawal . ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE is classified as Category A/B. Acetaminophen: Generally considered low risk; no consistent evidence of teratogenicity in any trimester. Pentazocine: Limited human data; animal studies show no teratogenicity at c. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.